• Home

  • Documents

  • Opdivo INN: 'nivolumab' · Start of procedure: 17 September 2016 CHMP Co-Rapporteur Assessment...

If you can't read please download the document

Opdivo INN: 'nivolumab' · Start of procedure: 17 September 2016 CHMP Co-Rapporteur Assessment Report 16 November 2016 CHMP Rapporteur Assessment Report 21 November 2016 PRAC Rapporteur

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Tovanor Breezhaler, INN-glycopyrronium...Jens Heisterberg Co-Rapporteur: David Lyons The application was received by the EMA on 1 September 2011. Tovanor Breezhaler CHMP assessment

Tovanor Breezhaler, INN-glycopyrronium...Jens Heisterberg Co-Rapporteur: David Lyons The application was received by the EMA on 1 September 2011. Tovanor Breezhaler CHMP assessment

Documents
AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)OPDIVO, as monotherapy, is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)OPDIVO, as monotherapy, is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Documents
AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)€¦ · Attachment 1: Product AusPAR Opdivo nivolumab Bristol-Myers Squibb Australia Pty.Ltd. PM-2017-02209-1-4 FINAL 24 January

AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)€¦ · Attachment 1: Product AusPAR Opdivo nivolumab Bristol-Myers Squibb Australia Pty.Ltd. PM-2017-02209-1-4 FINAL 24 January

Documents
Assessment report - European Medicines Agency · March 2016. • The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP

Assessment report - European Medicines Agency · March 2016. • The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP

Documents
Keytruda, INN - pembrolizumab · CV Percent coefficient of variation = [standard deviation/mean] x 100 ... Updated CHMP Rapporteur Assessment Report 7 December 2016 Updated PRAC Rapporteur

Keytruda, INN - pembrolizumab · CV Percent coefficient of variation = [standard deviation/mean] x 100 ... Updated CHMP Rapporteur Assessment Report 7 December 2016 Updated PRAC Rapporteur

Documents
Opdivo, INN - nivolumab...Assessment report EMA/216066/2016 Page 7/84 2. Scientific discussion 2.1. Introduction Opdivo (nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody

Opdivo, INN - nivolumab...Assessment report EMA/216066/2016 Page 7/84 2. Scientific discussion 2.1. Introduction Opdivo (nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody

Documents
Assessment report - European Medicines Agency · Submission date 7 December 2015 Start of procedure: 3 January 2016 CHMP Rapporteur Assessment Report 18 February 2016 PRAC Rapporteur

Assessment report - European Medicines Agency · Submission date 7 December 2015 Start of procedure: 3 January 2016 CHMP Rapporteur Assessment Report 18 February 2016 PRAC Rapporteur

Documents
CHMP assessment report for paediatric use studies ......21 November 2013 EMA/CHMP/780068/2013 Committee for Medicinal Products for Human Use (CHMP) Synagis (Palivizumab) Procedure

CHMP assessment report for paediatric use studies ......21 November 2013 EMA/CHMP/780068/2013 Committee for Medicinal Products for Human Use (CHMP) Synagis (Palivizumab) Procedure

Documents
Opdivo® (nivolumab)

Opdivo® (nivolumab)

Documents
CHMP assessment report · 25 July 2013 . EMA/CHMP/456924/2013 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Xoterna Breezhaler . International non-proprietary

CHMP assessment report · 25 July 2013 . EMA/CHMP/456924/2013 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Xoterna Breezhaler . International non-proprietary

Documents
CHMP assessment report - European Medicines · PDF fileCommittee for Medicinal Products for Human Use (CHMP) CHMP assessment report . ... IKr Delayed rectifier potassium current

CHMP assessment report - European Medicines · PDF fileCommittee for Medicinal Products for Human Use (CHMP) CHMP assessment report . ... IKr Delayed rectifier potassium current

Documents
Opdivo® (nivolumab) - Magellan Provider 2 | OPDIVO® (nivolumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval

Opdivo® (nivolumab) - Magellan Provider 2 | OPDIVO® (nivolumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval

Documents
Introductions of the Rapporteur - 45th World Conference on ...barcelona.worldlunghealth.org/updates/body/2014-Union-rapporteur... · Introductions of the Rapporteur . Organizing

Introductions of the Rapporteur - 45th World Conference on ...barcelona.worldlunghealth.org/updates/body/2014-Union-rapporteur... · Introductions of the Rapporteur . Organizing

Documents
Assessment report · Submission date 21 November 2017 Start of procedure: 23 December 2017 CHMP Co-Rapporteur Assessment Report 19 February 2018 CHMP Rapporteur Assessment Report

Assessment report · Submission date 21 November 2017 Start of procedure: 23 December 2017 CHMP Co-Rapporteur Assessment Report 19 February 2018 CHMP Rapporteur Assessment Report

Documents
European Medicines Agency | - authorised...submitted on 16 August 2007 their dossier in response to the quality issues raised by the CHMP and EMEA. On 7 September 2007, the Rapporteur

European Medicines Agency | - authorised...submitted on 16 August 2007 their dossier in response to the quality issues raised by the CHMP and EMEA. On 7 September 2007, the Rapporteur

Documents
OPDIVO, INN-nivolumab

OPDIVO, INN-nivolumab

Documents
CHMP assessment report - European Medicines Agency€¦ · 22 May 2014 . EMA/CHMP/231450/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Gazyvaro

CHMP assessment report - European Medicines Agency€¦ · 22 May 2014 . EMA/CHMP/231450/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Gazyvaro

Documents
Checkmate 067: ~6.5-year follow-up of OPDIVO (nivolumab

Checkmate 067: ~6.5-year follow-up of OPDIVO (nivolumab

Documents
YOUR OPDIVO® (nivolumab) ACTION PLAN - The …themelanomanurse.org/wp-content/uploads/2017/07/OPDIVO-MULTIPA… · YOUR OPDIVO® (nivolumab) ACTION PLAN ... taken care of right away

YOUR OPDIVO® (nivolumab) ACTION PLAN - The …themelanomanurse.org/wp-content/uploads/2017/07/OPDIVO-MULTIPA… · YOUR OPDIVO® (nivolumab) ACTION PLAN ... taken care of right away

Documents
Ketoconazole HRA, INN-ketoconazole · Ketoconazole HRA Assessment report EMA/CHMP/534845/2014 Page 6/115 . 1.3. Steps taken for the assessment of the product . The Rapporteur and

Ketoconazole HRA, INN-ketoconazole · Ketoconazole HRA Assessment report EMA/CHMP/534845/2014 Page 6/115 . 1.3. Steps taken for the assessment of the product . The Rapporteur and

Documents
D80 assessment report - Overview & D120 LOQ template with ... · Web view89 of 100 Rev. 10.19 corr 1 Rapporteur

D80 assessment report - Overview & D120 LOQ template with ... · Web view89 of 100 Rev. 10.19 corr 1 Rapporteur

Documents
OPDIVO (nivolumab) injection, for intravenous use · 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively

OPDIVO (nivolumab) injection, for intravenous use · 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively

Documents
CHMP assessment report - European Medicines Agency · CHMP assessment report Envarsus EMA/CHMP/81205/2014 Page 5/118 . List of abbreviations . ADME Absorption and bioavailability,

CHMP assessment report - European Medicines Agency · CHMP assessment report Envarsus EMA/CHMP/81205/2014 Page 5/118 . List of abbreviations . ADME Absorption and bioavailability,

Documents
Patient Pocket Guide - OPDIVO · 2 3 Please see Important Safety Information for OPDIVO and YERVOY, including Boxed WARNING for YERVOY regarding immune-mediated side effects, on the

Patient Pocket Guide - OPDIVO · 2 3 Please see Important Safety Information for OPDIVO and YERVOY, including Boxed WARNING for YERVOY regarding immune-mediated side effects, on the

Documents
CHMP extension of indication variation assessment …...London, 24 July 2014 EMA/562197/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication variation

CHMP extension of indication variation assessment …...London, 24 July 2014 EMA/562197/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication variation

Documents
CHMP assessment report - Europa

CHMP assessment report - Europa

Documents
AUSTRALIAN PRODUCT INFORMATION OPDIVO …Attachment 1: Product information for AusPAR Opdivo Nivolumab BMS Australia PM-2017-03752-1-4 Final 6 August 2018 This Product information

AUSTRALIAN PRODUCT INFORMATION OPDIVO …Attachment 1: Product information for AusPAR Opdivo Nivolumab BMS Australia PM-2017-03752-1-4 Final 6 August 2018 This Product information

Documents
CHMP extension of indication variation assessment …...London, 25 April 2014 EMA/CHMP/220738/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication

CHMP extension of indication variation assessment …...London, 25 April 2014 EMA/CHMP/220738/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication

Documents
Assessment report - ema.europa.eu€¦ · CHMP Rapporteur Updated Assessment Report 17 April 2015 Opinion 23 April 2015 . 2. Scientific discussion 2.1. Introduction Invega tablets

Assessment report - ema.europa.eu€¦ · CHMP Rapporteur Updated Assessment Report 17 April 2015 Opinion 23 April 2015 . 2. Scientific discussion 2.1. Introduction Invega tablets

Documents
Special Rapporteur on Indigenous Peoples · Special Rapporteur on Indigenous Peoples

Special Rapporteur on Indigenous Peoples · Special Rapporteur on Indigenous Peoples

Documents